News

FDA Approves Zevaskyn for Rare, Genetic Skin Disorder
Zevaskyn is the first and only autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa ...
ABEO: Zevaskyn™ Approved by FDA; Raising Valuation to $11…
ABEO READ THE FULL ABEO RESEARCH REPORT Business Update Zevaskyn™ Approved by FDA On April 29, 2025, Abeona Therapeutics, Inc. (NASDAQ:ABEO) announced that the U.S. Food and Drug Administration (FDA) ...
FDA approves Abeona’s $3.1m cell therapy for rare skin disease
Abeona has won FDA approval for Zevaskyn, setting up a commercial challenge to Krystal Biotech in the rare skin disease ...
The Pharma Letter5h
FDA approves Abeona’s Zevaskyn
The US Food and Drug Administration (FDA) has approved Zevaskyn (prademagene zamikeracel) gene-modified cellular sheets, also ...
Becker's Hospital Review28m
FDA OKs gene therapy for skin condition
The FDA has approved Zevaskyn, the first gene-modified cellular therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosis, a rare genetic skin disorder. Made by Abeona ...
Contract Pharma3h
Abeona’s ZEVASKYN Gets FDA Nod for Rare Skin Disease
The U.S. Food and Drug Administration (FDA) has approved Abeona Therapeutics Inc.’s ZEVASKYN gene-modified cellular sheets.
MedPage Today on MSN20h
FDA OKs New Gene Therapy for Debilitating Skin Condition
Patients with the debilitating dermatologic condition are born with COL7A1 mutations in both gene copies, affecting the ...
Olean Times Herald20h
Historic achievement: FDA approval of Abeona Therapeutics’ ZEVASKYN accelerates momentum and expands treatment options for the EB community.
EB Research Partnership ("EBRP") invested in the work that led to ZEVASKYN at Stanford University under their pioneering ...
Crain's Cleveland Business23h
Cleveland company receives FDA approval for rare disease treatment
Cleveland-based Abeona Therapeutics Inc. (Nasdaq: ABEO) announced Tuesday, April 29, that it has received U.S. Food and Drug ...
Medscape22h
FDA Approves First One-Time Topical Treatment for Recessive Dystrophic Epidermolysis Bullosa Wounds
In a phase 3 trial, 81% of wounds treated with autologous cell sheet-based gene therapy showed ≥ 50% healing at 6 months, ...
Health and Me on MSN14h
FDA Greenlights Zevaskyn for Rare Genetic Skin Condition
With FDA approval, Zevaskyn is set to be a game-changer in the treatment of recessive dystrophic epidermolysis ...
MPR1d
Zevaskyn Approved for Recessive Dystrophic Epidermolysis Bullosa
The FDA has approved Zevaskyn (prademagene zamikeracel) for the treatment of recessive dystrophic epidermolysis bullosa, a rare genetic skin disorder.